INVENTIVA SA (6IV.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:6IV • FR0013233012
6IV.DE Key Statistics, Chart & Performance
The current stock price of 6IV.DE is 5.29 EUR.
6IV.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 6IV.DE.
6IV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to 6IV.DE. Both the profitability and financial health of 6IV.DE have multiple concerns.
6IV.DE Financial Highlights
Over the last trailing twelve months 6IV.DE reported a non-GAAP Earnings per Share(EPS) of -3.62. The EPS decreased by -74.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -173.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
6IV.DE Forecast & Estimates
14 analysts have analysed 6IV.DE and the average price target is 13.46 EUR. This implies a price increase of 154.46% is expected in the next year compared to the current price of 5.29.
For the next year, analysts expect an EPS growth of 45.26% and a revenue growth 1.86% for 6IV.DE
6IV.DE Ownership
6IV.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.23 | 44.408B | ||
| 1AE | ARGENX SE | 28.28 | 44.383B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.29B | ||
| 2X1 | ABIVAX SA | N/A | 7.491B | ||
| ABVX | ABIVAX SA | N/A | 7.46B | ||
| GXE | GALAPAGOS NV | N/A | 1.918B | ||
| GLPG | GALAPAGOS NV | N/A | 1.915B | ||
| IVA | INVENTIVA SA | N/A | 973.063M | ||
| NANO | NANOBIOTIX | N/A | 880.66M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 6IV.DE
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
INVENTIVA SA
50 rue de Dijon, Daix
Daix OCCITANIE FR
Employees: 116
Phone: 33380447500
INVENTIVA SA / 6IV.DE FAQ
Can you describe the business of INVENTIVA SA?
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 84 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
What is the stock price of INVENTIVA SA today?
The current stock price of 6IV.DE is 5.29 EUR. The price increased by 6.44% in the last trading session.
Does 6IV stock pay dividends?
6IV.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of 6IV stock?
6IV.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists 6IV stock?
6IV.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the employee count for 6IV stock?
INVENTIVA SA (6IV.DE) currently has 116 employees.
Can you provide the market cap for INVENTIVA SA?
INVENTIVA SA (6IV.DE) has a market capitalization of 1.02B EUR. This makes 6IV.DE a Small Cap stock.